Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Radioligand Therapy Market Growth Potential: How Will Market Size Shift Through 2030?
The radioligand therapy market size has seen rapid growth in recent years. It is anticipated to expand from $6.63 billion in 2025 to $7.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.4%. The historical growth of this market can be attributed to factors such as the limited availability of radioligands, the reliance on conventional cancer therapies, growing awareness of the benefits of targeted therapy, increasing hospital adoption of nuclear medicine techniques, and regulatory approvals for early RLT drugs.
The radioligand therapy market is poised for significant expansion in the coming years. Its market size is projected to reach $10.72 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.0%. This anticipated growth within the forecast period is attributable to several factors, including the ongoing development of novel alpha and beta emitters, the broadening application of combined emission therapies, its integration with precision oncology, an increase in clinical trials targeting neurological and cardiovascular conditions, and rising investments in home care and outpatient RLT services. Prominent trends for the forecast period encompass the increasing adoption of targeted radioligand therapy in oncology, the expansion of alpha and beta emitter-based treatments, the incorporation of radioligand therapy with personalized medicine approaches, growth in hospital and research institution-based RLT programs, and an elevated focus on minimizing side effects while enhancing patient outcomes.
Get A Free Sample Report With In-Depth Market Insights:
Radioligand Therapy Market Expansion Drivers: What’s Shaping Future Growth?
The anticipated rise in cancer cases is projected to fuel the expansion of the radioligand therapy market in the future. Cancer is characterized by the unchecked proliferation of aberrant cells, which can infiltrate adjacent tissues and metastasize across the body. The surge in cancer prevalence is attributed to prolonged exposure to environmental contaminants, leading to DNA damage, cellular dysfunction, and the fostering of abnormal cell development. Radioligand therapy offers a treatment for cancer by delivering radiation directly to tumor cells via ligands that attach to specific receptors, thereby reducing damage to healthy tissues while internally eliminating cancerous cells. For example, as reported by the National Health Service (NHS), a government health agency in the UK, in October 2025, new cancer diagnoses totaled 354,820 in 2023, averaging 972 daily. This figure represents an increase of 8,605 compared to 2022. Consequently, the rising occurrence of cancer is a key factor boosting the radioligand therapy market’s growth.
Radioligand Therapy Market Segment Analysis: What Are The Core Market Categories?
The radioligand therapy market covered in this report is segmented –
1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions
2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets
3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral
4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases
5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings
Subsegments:
1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)
2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)
3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)
4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)
Radioligand Therapy Market Strategic Trends: What Defines The Next Growth Phase?
Major companies operating in the radioligand therapy market are focusing on developing advanced solutions, such as radioligand therapy facilities, to enhance production efficiency and maintain consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. These specialized radioligand therapy centers are designed to handle and deliver radioactive drugs for targeted cancer treatment using advanced imaging systems and radiation shielding, ensuring safety through trained personnel and strict protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This facility received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility is the largest and most advanced Novartis site dedicated to RLT, designed for efficient, time-sensitive production, and includes plans for fully automated production lines, enabling substantial supply increases to meet growing patient demand in the US and Canada.
Radioligand Therapy Market Top Companies Driving Competitive Growth
Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.
View The Full Radioligand Therapy Market Report:
Radioligand Therapy Market Regional Analysis And Top Geography
North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model